TRIAMCINOLONE ACETONIDE- triamcinolone acetonide lotion E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.


TRIAMCINOLONE ACETONIDE LOTION USP, 0.025%, 0.1%

Rx only

DESCRIPTION:

Triamcinolone Acetonide USP is a topical corticosteroid designated chemically as 9-Fluoro- 11β , 16α ,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with acetone.

Structural formula:



C₂₄H₃₁FO₆, MW 434.51

Each mL of 0.025% and 0.1% Triamcinolone Acetonide Lotion USP, provides 0.25 mg and 1 mg triamcinolone acetonide USP, respectively, in a lotion base containing propylene glycol, cetyl alcohol, stearyl alcohol, sorbitan monopalmitate, polysorbate 20, simethicone, and purified water.

CLINICAL PHARMACOLOGY:

Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids. There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

Pharmacokinetics: The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings.

Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (see **DOSAGE AND ADMINISTRATION**). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

INDICATIONS AND USAGE:

Triamcinolone Acetonide Lotion USP, 0.025% and 0.1% are indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

CONTRAINDICATIONS:

Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparations.

PRECAUTIONS:

General: Systemic absorption of topical corticosteroids has produced reversible hypothalamicpituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients.

Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings.

Therefore, patients receiving a large dose of any potent topical steriod applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests. If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application or to substitute a less potent steroid.

Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (see **PRECAUTIONS, Pediatric Use**).

If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

These preparations are not for ophthalmic use.

Information for the Patient: Patients using topical corticosteroids should receive the following information and instructions:

- 1. This medication is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.
- 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
- 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.
- 4. Patients should report any signs of local adverse reactions especially under occlusive dressing.
- 5. Parents of pediatric patients should be advised not to use tight fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

Laboratory Tests: A urinary free cortisol test and ACTH stimulation test may be helpful in evaluating HPA axis suppression.

Carcinogenesis, Mutagenesis, and Impairment of Fertility: Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone showed negative results.

Pregnancy: Teratogenic Effects - Pregnancy Category C: Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

Nursing Mothers: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

Pediatric Use: Pediatric patients may demonstrate greater susceptibility to topical corticos teroidinduced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. HPA axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticos teroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticos to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticos teroid therapy may interfere with the growth and development of children.

ADVERSE REACTIONS:

The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria.

OVERDOSAGE:

Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (see **PRECAUTIONS, General**).

DOSAGE AND ADMINISTRATION:

Apply the 0.025% Triamcinolone Acetonide Lotion to the affected area three to four times daily depending on the severity of the condition.

Apply the 0.1% Triamcinolone Acetonide Lotion to the affected area three to four times daily depending on the severity of the condition.

Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

HOW SUPPLIED

Triamcinolone Acetonide Lotion USP, 0.025%; plastic squeeze bottles containing 60 mL NDC 0168-0336-60 Triamcinolone Acetonide Lotion USP, 0.1%; plastic squeeze bottles containing 60 mL NDC 0168-0337-60

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].

AVOID FREEZING.

SHAKE WELL BEFORE USING.

E. FOUGERA & CO. A division of Fougera PHARMACEUTICALS INC. Melville, New York 11747

I2337D R05/15 #69

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 0.025% 60 mL CONTAINER

NDC 0168-0336-60

FOUGERA[®]

TRIAMCINOLONE ACETONIDE LOTION USP, 0.025%

60 mL

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

Rx only

E. FOUGERA & CO. A division of Fougera Pharmaceuticals Inc. Melville, New York 11747



PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 0.025% 60 mL CARTON

NDC 0168-0336-60

FOUGERA[®]


TRIAMCINOLONE ACETONIDE LOTION USP, 0.025%

60 mL

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

Rx only

E. FOUGERA & CO. A division of Fougera Pharmaceuticals Inc. Melville, New York 11747



PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 0.1% 60 mL CONTAINER

NDC 0168-0337-60 FOUGERA[®] TRIAMCINOLONE

ACETONIDE LOTION USP, 0.1%

60 mL

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

Rx only

E. FOUGERA & CO. A division of Fougera Pharmaceuticals Inc. Melville, New York 11747



PACKAGE LABEL - PRINCIPAL DISPLAY PANEL - 0.1% 60 mL CARTON

NDC 0168-0337-60

FOUGERA[®]


TRIAMCINOLONE ACETONIDE LOTION USP, 0.1%

60 mL

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

Rx only

E. FOUGERA & CO. A division of Fougera Pharmaceuticals Inc. Melville, New York 11747



TRIAMCINOLONE ACETONIDE

triamcinolone acetonide lotion

Product Information

Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC.0168-0336 Route of Administration TOPICAL Active Ingredient/Active Moiety Basis of Strength Strength Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength Strength Triancinolone Acetonide (UNIE F446/C597KA) Ingredient Name 0.25 mg Acetonide 0.25 mg Instructive Ingredient/Strength Ingredient Name Strength In 1 mL Propylene glycol (UNIE 6DC9Q167V3) Strength Strength starty latohol (UNIE 353/575/CN) Strength Strength propylene glycol (UNIE 7765/2421KU) Strength Strength polysorbate 20 (UNIE 71F30 V5YH) Strength Strength silicon dioxide (UNIE 37262421KU) Strength Strength polysorbate 20 (UNIE 71F30 V5YH) Strength Strength Silicon Source (UNIE 92RUSNATION) Strength Strength J NOC.0168-0336-60 In 1 CARTON Marketing Start Date Marketing End Date 1 NOC.0168-0336-60 In 1 CARTON Strength Marketing End Date 1 NOC.0168-0336-60						110.0			
Active Ingredient/Active Moiety Ingredient Name Ingredient Nam	Product Type		HUMAN PRESCRIPTION DRUG	Item Code	e (Source)	NDC	:0168-0336		
Ingredient Name Basis of Strength Strength Triamcinolone Acetonide (UNE: F446C597KA) (Triamcinolone Acetonide - UNE: F446C597KA) Triamcinolone Acetonide 0.25 mg in 1 mL Ingredient Name Triamcinolone Acetonide Triamcinolone Acetonide 0.25 mg in 1 mL Ingredient Name Strength propylene glycol (UNE: 6DC9Q167V3) Strength Strength strength propylene glycol (UNE: 6DC9Q167V3) Strength strength propylene glycol (UNE: 6DC9Q167V3) Strength strength <td col<="" th=""><th>Route of Administra</th><th>tion</th><th>TOPICAL</th><th></th><th></th><th></th><th></th></td>	<th>Route of Administra</th> <th>tion</th> <th>TOPICAL</th> <th></th> <th></th> <th></th> <th></th>	Route of Administra	tion	TOPICAL					
Ingredient Name Basis of Strength Strength Triamcinolone Acetonide (UNE: F446C597KA) (Triamcinolone Acetonide - UNE: F446C597KA) Triamcinolone Acetonide 0.25 mg in 1 mL Ingredient Name Triamcinolone Acetonide Triamcinolone Acetonide 0.25 mg in 1 mL Ingredient Name Strength propylene glycol (UNE: 6DC9Q167V3) Strength Strength strength propylene glycol (UNE: 6DC9Q167V3) Strength strength propylene glycol (UNE: 6DC9Q167V3) Strength strength <td col<="" th=""><th></th><th></th><th></th><th></th><th></th><th></th><th></th></td>	<th></th> <th></th> <th></th> <th></th> <th></th> <th></th> <th></th>								
Ingredient Name Basis of Strength Strength Triamcinolone Acetonide (UNE: F446C597KA) (Triamcinolone Acetonide - UNE: F446C597KA) Triamcinolone Acetonide 0.25 mg in 1 mL Ingredient Name Triamcinolone Acetonide Triamcinolone Acetonide 0.25 mg in 1 mL Ingredient Name Strength propylene glycol (UNE: 6DC9Q167V3) Strength Strength strength propylene glycol (UNE: 6DC9Q167V3) Strength strength propylene glycol (UNE: 6DC9Q167V3) Strength strength <td col<="" th=""><th>A</th><th></th><th>- h</th><th></th><th></th><th></th><th></th></td>	<th>A</th> <th></th> <th>- h</th> <th></th> <th></th> <th></th> <th></th>	A		- h					
Triamcinolone Acetonide Triamcinolone Acetonide 0.25 mg in 1 ml. UNEF446C597KA) in 1 ml. Acetonide in 1 ml. Ingredient Name Strength	Active Ingredien								
UNEF446C597KA) Aceconide in 1 mL Aceconide in 1 mL Ingredient Name Strength Forpylene glycol (UNE 6DC9Q167V3) Strength cetyl alcohol (UNE 2KR994HIY) Strength sorbitar monopalmitate (UNE 77K62421KU) Sorbitar monopalmitate (UNE 77K62421KU) Sorbitar Dotol (UNE: 77K62421KU) Sorbitar Dotol (UNE: 77K62421KU) Sorbitar Dotol (UNE: 92F0KOVF) Sorbitar Dotol (UNE: 92F0KOVF) Sorbitar Dotol (UNE: 92R03N3YIO) Sorbitar Dotol (UNE: 92R03N3YIO) Sorbitar Dotol (UNE: 92R03N3YIO) Marketing End Date Marketing Information Product Marketing End Date NoColobe: 0 in 1 CARTON Marketing Cate gory Marketing Cate gory Application Number or Monograph Citation <td colsp<="" th=""><th></th><th></th><th></th><th></th><th></th><th>ength</th><th></th></td>	<th></th> <th></th> <th></th> <th></th> <th></th> <th>ength</th> <th></th>						ength		
Ingredient Name Strength propylene glycol (UNIE: 6DC9Q167V3) cetyl alcohol (UNIE: 936JST6JCN) Strength stearyl alcohol (UNIE: 936JST6JCN) Strength stearyl alcohol (UNIE: 936JST6JCN) Strength Strength <td <="" colspan="2" strength<="" th=""><th></th><th>nide (UNII: F446</th><th>C597KA) (Triamcinolone Acetonide -</th><th></th><th></th><th></th><th>-</th></td>	<th></th> <th>nide (UNII: F446</th> <th>C597KA) (Triamcinolone Acetonide -</th> <th></th> <th></th> <th></th> <th>-</th>			nide (UNII: F446	C597KA) (Triamcinolone Acetonide -				-
Ingredient Name Strength propylene glycol (UNIE: 6DC9Q167V3) cetyl alcohol (UNIE: 936JST6JCN) Strength stearyl alcohol (UNIE: 936JST6JCN) Strength stearyl alcohol (UNIE: 936JST6JCN) Strength Strength <td <="" colspan="2" strength<="" td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td></td>	<td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>								
propylene glycol (UNIE 6DC9Q 167V3) cetyl alcohol (UNIE 936 JST6 JCN) stearyl alcohol (UNIE 97K62421KU) polysorbate 20 (UNIE 77K62421KU) polysorbate 20 (UNIE 77K6241KU) polysorbate 20 (UNIE 77K641KU) polysorbate 20 (UNIE 77K641KU) polysorbate 20 (UNIE 77K641KU) polysorbate 20 (UNIE	Inactive Ingredie	nts							
cetyl alcohol (UNIE 936JST6JCN) idea stearyl alcohol (UNIE 97K6Z421KU) idea polysorbate 20 (UNIE 7TF30V5YH) idea silicon dioxide (UNIE 7TF30V5YH) idea silicon dioxide (UNIE 53QF0KOUR) idea polysorbate 20 (UNIE 7TF30V5YH) idea water (UNIE 55QF0KOUR) idea polysorbate 20 (UNIE 7TF30V5YH) idea water (UNIE 55QF0KOUR) idea polysorbate 20 (UNIE 7TF30V5YH) idea water (UNIE 55QF0KOUR) idea polysorbate 20 (UNIE 7TF30V5YH) idea water (UNIE 55QF0KOUR) idea polysorbate 20 (UNIE 7TF30V5YH) idea polysorbate 20 (UNIE 7TF30V5YH) idea polysorbate 20 (UNIE 50QF0KOUR) idea			Ingredient Name			S	trength		
stearyl alcohol (UNII: 2KR8914HY) sorbitan monopalmitate (UNII: 77K62421KU) polysorbate 20 (UNII: 7T1F30V5YH) silicon dioxide (UNII: 5TJ76XBU4) water (UNII: 059QF0KOR) DIMETHICONE (UNII: 92RU3N3Y1O) Packageing # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:0168-0336-60 1 in 1 CARTON 1 Marketing Information Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA04067 04/21/2003 NDC:0168-0336-01 CARTONIDE	propylene glycol (UN	II: 6 DC9 Q 16 7 V3)						
sorbitan monopalmitate (UNII: 77K6Z421KU)	cetyl alcohol (UNII: 93	36JST6JCN)							
polysorbate 20 (UNE: 7TJF30V5YH) silicon dioxide (UNE: ETJ7Z6XBU4) Image: Comparison of the	stearyl alcohol (UNII:	2KR89I4H1Y)							
silicon dioxide (UNII: ETJ7Z6XBU4) → Silicon dioxide (UNII: DTJ7Z6XBU4) → Silicon dioxide (UNII: DTTZ6XBU4) → Silicon dioxide (UNII: DTTZ6XBU4) → Silicon dioxide (UNII: DTTTC0XBUA) → Silicon dioxide (UNII: DTTTTC0XBUA) → Silicon dioxide (UNII: DTTTTC0XBUA) → Silicon dioxide di	sorbitan monopalmit	ate (UNII: 77K62	Z421KU)						
water (UNII: 059QF0KUTR) Image: Constraint of the second seco	polysorbate 20 (UNII:	7T1F30V5YH)							
DIMETHICONE (UNIE 92RU3N3Y10) Image: Second Sec	silicon dioxide (UNII:	ETJ7Z6 XBU4)							
Packaging # Item Code Package Description Marketing Start Date Marketing End Date 1 NDC:0168-0336-60 1 in 1 CARTON 1 <t< td=""><td>water (UNII: 059QF0K</td><td>O0R)</td><td></td><td></td><td></td><td></td><td></td></t<>	water (UNII: 059QF0K	O0R)							
Item Code Package Description Marketing Start Date Marketing End Date NDC:0168-0336-60 1 in 1 CARTON Image: Carter of the start of the sta	DIMETHICO NE (UNII:	92RU3N3Y1O)							
Item Code Package Description Marketing Start Date Marketing End Date NDC:0168-0336-60 1 in 1 CARTON Image: Carter of the start of the sta									
Item Code Package Description Marketing Start Date Marketing End Date NDC:0168-0336-60 1 in 1 CARTON Image: Carter of the start of the sta									
1 NDC:0168-0336-60 1 in 1 CARTON Image: Carterian of the state of the st	Packaging								
10mL in 1BOTTLE; Type 0: Not a Combination ProductImage: Comparison of the second sec	# Item Code		Package Description	Marketin	ig Start Date	Marke	ting End Date		
Marketing Information Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA040467 04/21/2003 04/21/2003	1 NDC:0168-0336-60	1 in 1 CARTON			-		-		
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA040467 04/21/2003 04/21/2003 TRIAMCINOLONE ACETONIDE Vertical Action Start Date Vertical Action Start Date	1	60 mL in 1 BOT	TLE; Type 0: Not a Combination Product						
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA040467 04/21/2003 04/21/2003 TRIAMCINOLONE ACETONIDE Vertical Action Start Date Vertical Action Start Date									
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA040467 04/21/2003 04/21/2003 TRIAMCINOLONE ACETONIDE Vertical Action Start Date Vertical Action Start Date									
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date ANDA ANDA040467 04/21/2003 04/21/2003 TRIAMCINOLONE ACETONIDE Vertical Action Start Date Vertical Action Start Date		•							
ANDA ANDA040467 04/21/2003 TRIAMCINOLONE ACETONIDE	Marketing Inf	ormation							
TRIAMCINOLONE ACETONIDE	Marketing Categor	y Applicatio	on Number or Monograph Citation	Marketin	g Start Date	Marke	ting End Date		
	ANDA	ANDA040467	7	04/21/2003					
	TRIAMCINOI	ONE ACE	TONIDE						

Product Information			
Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0168-0337
Route of Administration	TOPICAL		

Active Ingredient/Active Moiety		
Ingredient Name	Basis of Strength	Strength
Triamcinolone Acetonide (UNII: F446C597KA) (Triamcinolone Acetonide - UNII:F446C597KA)	Triamcino lo ne Aceto nide	1 mg in 1 mL

	active Ingredie	nts		
		Ingredient Name		Strength
pro	opylene glycol (UN	II: 6DC9Q167V3)		
cet	yl alcohol (UNII: 93	36JST6JCN)		
ste	aryl alcohol (UNII:	2KR89I4H1Y)		
sor	rbitan monopalmit	ate (UNII: 77K6Z421KU)		
pol	lysorbate 20 (UNII:	7T1F30V5YH)		
sili	icon dioxide (UNII:	ETJ7Z6XBU4)		
wa	ter (UNII: 059QF0K	00R)		
DI	METHICO NE (UNII:	92RU3N3Y1O)		
	nckaging			
#	Item Code	Package Description	Marketing Start Date	Marketing End Date
#	0 0	1 in 1 CARTON	Marketing Start Date	Marketing End Date
# 1 I	Item Code	2	Marketing Start Date	Marketing End Date
#	Item Code	1 in 1 CARTON	Marketing Start Date	Marketing End Date
# 1 1 1	Item Code	1 in 1 CARTON 60 mL in 1 BOTTLE; Type 0: Not a Combination Product	Marketing Start Date	Marketing End Date
# 1 I 1	Item Code NDC:0168-0337-60	1 in 1 CARTON 60 mL in 1 BOTTLE; Type 0: Not a Combination Product ormation	Marketing Start Date Marketing Start Date	Marketing End Date
# 1 1 1 1 M	Item Code NDC:0168-0337-60	1 in 1 CARTON 60 mL in 1 BOTTLE; Type 0: Not a Combination Product ormation y Application Number or Monograph Citation		

Labeler - E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. (043838424)

Revised: 5/2015

E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.